CN105949305A - Sept2截短体及其载体和应用 - Google Patents
Sept2截短体及其载体和应用 Download PDFInfo
- Publication number
- CN105949305A CN105949305A CN201610514329.9A CN201610514329A CN105949305A CN 105949305 A CN105949305 A CN 105949305A CN 201610514329 A CN201610514329 A CN 201610514329A CN 105949305 A CN105949305 A CN 105949305A
- Authority
- CN
- China
- Prior art keywords
- sept2
- polypeptide
- truncated
- application
- liver cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150104604 SEPTIN2 gene Proteins 0.000 title claims abstract description 40
- 239000013598 vector Substances 0.000 title description 9
- 102000007327 Protamines Human genes 0.000 title 1
- 108010007568 Protamines Proteins 0.000 title 1
- 229940048914 protamine Drugs 0.000 title 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 24
- 201000007270 liver cancer Diseases 0.000 abstract description 20
- 208000014018 liver neoplasm Diseases 0.000 abstract description 20
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 20
- 229920001184 polypeptide Polymers 0.000 abstract description 18
- 238000002474 experimental method Methods 0.000 abstract description 9
- 238000011161 development Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 239000013604 expression vector Substances 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 3
- 230000002380 cytological effect Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 22
- 108010087230 Sincalide Proteins 0.000 description 6
- 238000010609 cell counting kit-8 assay Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 4
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 3
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 108050004875 Septin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了Sept2截短体及其载体和应用。Sept2截短体，其氨基酸序列如SEQ ID NO.1所示。本发明利用生物工程技术基因重组一段308个氨基酸多肽对应的DNA序列到p3*flag‑cmv‑13‑14真核表达载体。细胞学实验表明此多肽具有抑制肝癌细胞活性和生长的重要抗癌功能。发明为肿瘤治疗开发新的靶点提供实验依据，对于应用于肿瘤的临床治疗具有十分重要的开发应用前景。
Description
技术领域
本发明涉及生物工程技术领域，具体是Sept2截短体及其载体和应用。
背景技术
肝细胞肝癌(Hepatocellular carcinoma，HCC)是最常见的恶性肿瘤之一，其发病率在全球恶性肿瘤中居第五位，死亡率居第三位，具有起病隐匿、发展迅速、预后差、转移率高等特点，已成为危害人类健康的重要疾病。因此，加强治疗肝癌的研究，探索新的治疗途径具有十分重要的意义。
在肝癌进展过程中，某些基因的表达发生变化，是肝癌发生发展的关键基因，成为肝癌治疗的潜在靶点。现有研究发现肝癌组织中的表达蛋白缺少某段多肽序列后不仅丧失了抑癌功能并且促进肝癌生长，故推测此多肽具有抑癌效应。Sept2是Septins基因家族一种能够调节微管蛋白的基因，它可通过微管蛋白调节G2/M期转换和细胞有丝分裂，在纺锤体的形成和姊妹染色单体的分离中也发挥重要作用；而干扰Sept2可导致有丝分裂的失败和细胞的多核化以及引起细胞周期阻滞等。并且发现Sept2的某段多肽片段的外源性过表达，会阻断野生型Sept2的作用，从而起到抑癌作用。所以，在此发明中我们利用基因重组技术，Sept2的308氨基酸(amino acid)多肽对应的DNA序列重组到p3*flag-cmv-13-14真核表达载体。经酶切和序列分析证明重组成功后，将此真核表达重组多肽转染到肝癌细胞，免疫印迹证明多肽的蛋白表达，实现了多肽的重组。将表达多肽序列的重组真核载体转染到肝癌细胞中，证明其独特的抑制肝癌生长和抑制肝癌发生的抗癌效应。发明为肝癌治疗开发新的靶点提供实验依据，对于应用于肝癌的临床治疗具有十分重要的开发应用前景。
发明内容
发明目的：针对现有技术中存在的不足，本发明的目的是提供一种Sept2截短体，具有抗肝癌的应用价值。本发明的另一目的是提供上述Sept2截短体的表达载体。本发明还有一目的是提供上述Sept2截短体的应用。
技术方案：为了实现上述发明目的，本发明采用的技术方案为：
Sept2截短体，其氨基酸序列如SEQ ID NO.1所示。
编码所述的Sept2截短体的基因，其DNA序列如SEQ ID NO.2所示。
含有所述的Sept2截短体的编码基因的DNA序列的载体。
所述的载体，将Sept2截短体的DNA序列连接进p3*flag-cmv-13-14真核表达载体，构建出重组表达质粒。
所述的Sept2截短体在制备抗肿瘤药物中的应用。
有益效果：与现有技术相比，本发明利用生物工程技术，基因重组一段308个氨基酸多肽对应的DNA序列到p3*flag-cmv-13-14真核表达载体，经酶切和序列分析证明重组成功后，将此真核表达重组多肽转染到肝癌细胞中，免疫印迹证明多肽的蛋白表达，实现了多肽的重组。接着对多肽的抗肝癌功能进行了研究，细胞学实验表明此多肽具有抑制肝癌细胞活性的重要抗癌功能，在制备抗肿瘤药物中的将具有广泛的应用，为肿瘤治疗开发新的靶点提供实验依据，对于应用于肿瘤的临床治疗具有十分重要的开发应用前景。
附图说明
图1是Sept2截短体免疫印迹蛋白表达结果电泳图；大小为34KD；
图2是PI染色流式细胞术检测Sept2截短体抑制HepG2细胞增殖结果图；
图3是CCK-8实验检测Sept2截短体对HepG2活性的抑制结果图；
图4是EDU实验检测Sept2截短体抑制Huh7细胞增殖结果图；
图5是EDU实验检测Sept2截短体抑制Huh7细胞增殖柱状图。
具体实施方式
下面结合具体实施例对本发明作进一步的说明。实施例中未注明具体条件的实验方法，通常按照常规条件，例如分子克隆实验指南(第三版，J.萨姆布鲁克等著，黄培堂等译，科学出版社，2002年)中所述的条件，或按照制造厂商所建议的条件进行。
实施例1重组肽的克隆载体构建
提取人的mRNA，逆转录为cDNA，以cDNA为模板，上游引物为5’-TGCAAGCTTACCATGTCTAAGCAACAGCCAACTC-3’(含HindⅢ酶切位点)；下游引物为5’-TCGGAATTCCCGCCTCTCTTGAGTCTC-3’(含EcoR1酶切位点)，应用PCR技术成功扩增出Sept2截短体(SEQ ID NO.1所示)对应的924bp的mRNA序列(SEQ ID NO.2所示)。扩增得到的片段与p3*flag-cmv-13-14载体连接，将连接产物转入感受态大肠杆菌DH5α中，在含Amp+琼脂平板上挑选克隆，以碱裂解法小提重组质粒后，以ECOR1酶切鉴定。
实施例2重组肽的真核表达载体构建及其表达鉴定
将含有Sept2截短体的p3*flag-cmv-13-14质粒经ECOR1酶切后，利用回收试剂盒获得该片段，同时用相同的酶处理质粒p3*flag-cmv-13-14，然后将回收多肽核酸片段和经酶切的载体pcDNA3.1在T4DNA连接酶作用下于16℃连接过夜。酶切鉴定重组体。将正确连接的Sept2截短体真核表达载体转染HepG2细胞，48小时后搜集样品，RIPA细胞裂解液裂解，免疫印迹结果证明了多肽的表达，如图1所示为Sept2截短体，大小为34KD。
实施例3重组肽抗肝癌功能的检测
1)PI染色流式细胞术实验证明重组肽细胞水平的抗肝癌效应
PI染色流式细胞分析术检测细胞周期：在Huh7和HepG2等HCC细胞中，转染野生型、Sept2截短体的Sept2载体48h后，胰酶消化细胞，完全培养基终止消化并收集到5mL EP管中离心后弃掉培养基，用预冷的细胞PBS重悬洗涤3次，离心，弃掉PBS，用70％乙醇重悬，置于-20℃固定至少24h。检测前，离心收集的细胞，弃乙醇，用PBS洗涤3次，并用含1％Triton X-100的PBS，4℃通透，每管200μL。后加入RNaseA，避光4℃反应，每管300-400μL。加入200μL PI染色剂，避光4℃染色20min，每管200μL，流式细胞仪检测。结果如图2：相对于对照组而言，转染Sept2截短体(Sept2△1-308aa)比转染野生型Sept2细胞S期和G2期比例有明显的降低说明Sept2△1-308aa能引起细胞增殖阻滞。
2)CCK-8实验证明重组肽细胞水平的抗肝癌效应
CCK-8细胞增殖实验：在Huh7和HepG2等HCC细胞中，转染野生型，308aa片段截短的Sept2载体48h后收集细胞，每孔5000个细胞接种到96孔板，每孔体积100μL。待细胞完全贴壁后(根据实验目的和实际情况决定培养时间)，每孔换液(CCK-8与培养液的比例为1:10)，37℃孵育2h，终止培养，酶标仪以490nm波长测量各孔的吸光度值，每组设四复孔。每24h测定各组CCK-8吸光度值一次，共检测5天，以时间为横坐标，吸光值为纵坐标绘制细胞生长曲线。结果如图3。同样，CCK-8也显示转染Sept2△1-308aa组比转染对照组细胞增殖明显抑制。
3)EDU掺入实验证明重组肽细胞水平的抗肿瘤效应
将HepG2分别以每孔4×103～1×105细胞接种于96孔板中，利用Lipofectamin 2000kit将308aa片段截短的Sept2载体瞬时转染HepG2细胞，48h后进行EDU孵育(50nM)，2小时后弃培养基，而后通过细胞固定、Apollo染色、DNA染色后，进行观测并统计。结果如图4和图5显示，同样验证了该实验结果。
Claims (5)
1.Sept2截短体，其氨基酸序列如SEQ ID NO.1所示。
2.编码权利要求1所述的Sept2截短体的基因，其DNA序列如SEQ IDNO.2所示。
3.含有权利要求2所述的Sept2截短体的编码基因的DNA序列的载体。
4.根据权利要求3所述的载体，其特征在于：将Sept2截短体的DNA序列连接进p3*flag-cmv-13-14真核表达载体，构建出重组表达质粒。
5.权利要求1所述的Sept2截短体在制备抗肿瘤药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610514329.9A CN105949305A (zh) | 2016-06-30 | 2016-06-30 | Sept2截短体及其载体和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610514329.9A CN105949305A (zh) | 2016-06-30 | 2016-06-30 | Sept2截短体及其载体和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105949305A true CN105949305A (zh) | 2016-09-21 |
Family
ID=56903186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610514329.9A Pending CN105949305A (zh) | 2016-06-30 | 2016-06-30 | Sept2截短体及其载体和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105949305A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114716529A (zh) * | 2022-03-18 | 2022-07-08 | 孙英贤 | Septin4突变基因及其制药用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000060066A1 (en) * | 1999-04-01 | 2000-10-12 | Curagen Corporation | Protein-protein from s. cerevisiae and methods of using same |
-
2016
- 2016-06-30 CN CN201610514329.9A patent/CN105949305A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000060066A1 (en) * | 1999-04-01 | 2000-10-12 | Curagen Corporation | Protein-protein from s. cerevisiae and methods of using same |
Non-Patent Citations (5)
| Title |
|---|
| CAO LQ 等: "septin-2 isoform a [Homo sapiens]", 《GENBANK DATABASE》 * |
| LIANG-QI CAO 等: "Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression", 《CANCER LETTERS》 * |
| YI-WEI HUANG 等: "GTP binding and hydrolysis kinetics of human septin 2", 《FEBS JOURNAL》 * |
| 张军 等: "septin2基因短剪接本转表达产物对小鼠皮肤培养细胞作用的实验研究", 《中华整形外科杂志》 * |
| 陆东东 等: "肝癌组织中Septin1、Septin2、Septin6基因表达及其功能的初步研究", 《肿瘤研究与临床》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114716529A (zh) * | 2022-03-18 | 2022-07-08 | 孙英贤 | Septin4突变基因及其制药用途 |
| CN114716529B (zh) * | 2022-03-18 | 2024-05-14 | 孙英贤 | Septin4突变基因及其制药用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang et al. | Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma | |
| Li et al. | MiR-410 affects the proliferation and apoptosis of lung cancer A549 cells through regulation of SOCS3/JAK-STAT signaling pathway. | |
| Srivastava et al. | Recombinant adenovirus vector expressing wildtype p53 is a potent inhibitor of prostate cancer cell proliferation | |
| Liu et al. | Inhibition of miR-221 influences bladder cancer cell proliferation and apoptosis. | |
| Haley et al. | Altered transcriptional control networks with trans-differentiation of isogenic mutant-KRas NSCLC models | |
| Liang et al. | Zinc finger protein 307 functions as a tumor‑suppressor and inhibits cell proliferation by inducing apoptosis in hepatocellular carcinoma | |
| CN105949305A (zh) | Sept2截短体及其载体和应用 | |
| CN105749295A (zh) | RecQL4基因高表达作为靶点在制备抗胃癌药物中的应用 | |
| Li et al. | Accurately mapping the location of the binding site for the interaction between hepatitis B virus X protein and cytochrome c oxidase III | |
| Zhu et al. | Up-regulation of Let-7a expression induces gastric carcinoma cell apoptosis in vitro | |
| CN103191413B (zh) | Oct4b蛋白异构体的用途 | |
| Chen et al. | Transfection and expression of hepatitis B virus x gene and its effect on apoptosis in HL-7702 cells | |
| CN114957399B (zh) | 一种多肽、多肽衍生物及其在制备抗肿瘤药物中的应用 | |
| CN107164337B (zh) | 含ccl5和sstr2基因的重组痘病毒及其制备方法 | |
| Kanai et al. | Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non‐small cell lung cancer—expression of an RNA‐binding protein, Musashi1, as a marker for the tailored gene therapy | |
| CN109943580A (zh) | 一种双基因重组复合物巨噬细胞疫苗及其制备方法和应用 | |
| WO2007127347A2 (en) | An isolated dna fragment of the sparc human promoter and its use | |
| CN103114104A (zh) | 一种抑癌肽基因重组及其抗肿瘤应用 | |
| CN106110297B (zh) | Gfi1截短体的应用 | |
| CN106084028A (zh) | 324aa小分子多肽及其载体和应用 | |
| CN105693825A (zh) | 抑癌多肽127aa及其表达载体和应用 | |
| CN101671670B (zh) | 一种肝癌靶向性基因表达元件ap及其应用 | |
| CN105949285B (zh) | Rbbp5截短体的应用 | |
| CN105920583A (zh) | 183aa小分子多肽的应用 | |
| CN101805724B (zh) | 靶向性wwox基因重组腺病毒及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |